EBS FY 2009 Earnings — Emergent BioSolutions Inc. Revenue & Financial Results | Market Cap Arena

EBSEmergent BioSolutions Inc.

$424M

FY 2009 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$235M+31.5% YoY

Gross Profit

$189M80.3% margin

Operating Income

$40M17.1% margin

Net Income

$31M13.3% margin

EPS (Diluted)

$0.99

Cash Flow

Operating Cash Flow

$31M

Free Cash Flow

-$3M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$345M

Total Liabilities

$101M

Stockholders' Equity

$241M

Cash & Equivalents

$103M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$235M	$179M	+31.5%
Gross Profit	$189M	$144M	+30.5%
Operating Income	$40M	$30M	+34.2%
Net Income	$31M	$21M	+50.6%